DONALDSON Co INC acquired Purilogics, LLC for approximately $19.9 million (net of cash acquired); up to $29.0 million additional contingent consideration, a transaction completed in June 2022, structured as all cash plus contingent consideration.
Purilogics, LLC operates in Life Sciences, is based in Headquartered in Greenville, South Carolina. Purilogics is an early-stage biotechnology company that developed proprietary Purexa membrane chromatography products for the purification and streamlined manufacturing of biopharmaceuticals. Aimed initially at the purification of pDNA, mRNA and mAbs, the Purexa membrane platform offers competitive advantages over traditional resin and monolith technologies, enabling improved productivity, speed and production costs.
Adds membrane chromatography purification technology to Donaldson's bioprocessing portfolio.
Up to $29.0 million contingent consideration tied to developing manufacturing capabilities, creating future technologies and attaining business performance results. Life Sciences segment
On June 13, 2022, the Company acquired Purilogics, headquartered in Greenville, South Carolina, for cash consideration of approximately $19.9 million, net of cash acquired. The transaction included a maximum payout of $29.0 million in contingent consideration related to developing manufacturing capabilities, creating future technologies and attaining certain business performance results.Donaldson FY2022 10-K, Note 2 Acquisitions
Advisory firms were not disclosed for this transaction.